Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALLO 501

Next Previous
Drug Profile

ALLO 501

Alternative Names: ALLO-501; Anti-CD19 AlloCAR T; Anti-CD19 CAR T cell therapy - Allogene Therapeutics

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellectis
  • Developer Allogene Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported B-cell lymphoma; Follicular lymphoma

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in B-cell lymphoma(Combination therapy, Second-line therapy or greater) in USA (Parenteral)
  • 09 Dec 2023 Pooled adverse events data from the phase-I/II ALPHA-2 trial of cemacabtagene ansegedleucel and phase-I ALPHA trial of ALLO-501 trial in Diffuse large B cell lymphoma were presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 15 Jun 2023 Pooled efficacy and safety data from phase I/II ALPHA-2 trial of ALLO 501A and phase I ALPHA trial of ALLO 501 trial in Non-Hodgkin's lymphoma released by Allogene Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top